Intermediate-cyclophosphamide and bortezomib for peripheral blood stem cell mobilization in multiple myeloma
Phase 2
Recruiting
- Conditions
- multiple myeloma
- Registration Number
- JPRN-UMIN000011503
- Lead Sponsor
- Department of Hematology, Ishikawa Prefectural Central Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1.Uncontrollable organ dysfunction(liver dysfuction, renal insufficiency, cardiac dysfunction, respiratory dysfunction, diabetes mellitus, infection) 2.Pregnant female 3.HBsAg positive, HCVAb positive, HIVAb positive 4.Coexistence of malignancy 5.Serious mental disorders 6.Those who are considered as inappropriate to register by attending physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method umber of CD34 cells harvested Safety
- Secondary Outcome Measures
Name Time Method CR and CR+VGPR Incidence of graft failure
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie cyclophosphamide and bortezomib's synergy in multiple myeloma stem cell mobilization?
How does intermediate-dose cyclophosphamide plus bortezomib compare to standard high-dose cyclophosphamide for peripheral blood stem cell mobilization in multiple myeloma patients?
Which biomarkers correlate with successful peripheral blood stem cell collection in multiple myeloma patients treated with cyclophosphamide and bortezomib?
What are the incidence and management strategies for cytokine release syndrome in multiple myeloma patients undergoing cyclophosphamide-bortezomib mobilization therapy?
How does the combination of intermediate-cyclophosphamide and bortezomib compare to lenalidomide-based regimens for stem cell mobilization in multiple myeloma?